Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
1444836-94-4
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
Deciphera Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C28H32N8O
|
| gptkbp:hasSMILES |
CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NC=CN=C4N5CCN(CC5)C6=CN(N=C6)C
|
| gptkbp:hasUNII |
6Q1K1Q1K0E
|
| https://www.w3.org/2000/01/rdf-schema#label |
rebastinib
|
| gptkbp:investigatedBy |
gptkb:cancer
|
| gptkbp:IUPACName |
N-(4-(6-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)pyrazin-2-yl)phenyl)-4-(4-methylpiperazin-1-yl)benzamide
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:molecularWeight |
480.61 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3544947
71587768 58919613 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:VEGFR2
TIE2 receptor |
| gptkbp:bfsParent |
gptkb:Janus_kinases
gptkb:Tie2_receptor |
| gptkbp:bfsLayer |
8
|